Frequency of 17p Deletion in Chronic Lymphocytic Leukemia Patients Presenting to Combined Military Hospital Rawalpindi
DOI:
https://doi.org/10.51253/pafmj.v74i2.6530Keywords:
17p deletion, Chronic lymphocytic leukemia, Diagnosis, MutationsAbstract
Objective: To assess the frequency and factors related to the presence of 17p deletion among patients diagnosed with chronic lymphocytic leukaemia at the Oncology Department of Combined Military Hospital Rawalpindi
Study Design: Cross-sectional study.
Setting And Duration Of Study: Oncology Department, Combined Military Hospital, Rawalpindi Pakistan, Feb 2020 to Mar 2021.
Methodology: Patients with Chronic lymphocytic leukaemia were recruited for the study. The fluorescence in situ hybridization method was used to look for the presence of 17p deletion, using 10% cells as a cut-off value. Demographics, treatment status, and β2-microglobulin levels were correlated with 17p deletion in our study population.
Results: A total of 102 patients diagnosed with Chronic Lymphocytic leukaemia were included in the analysis. The mean age of the patients was 55.82±7.176 years.74(72.5%) were male, while 28(27.5%) patients diagnosed with this condition were female. 17p deletion was present in 16(15.7%) patients, while 86(84.3%) patients were not detected with 17p deletion. Elevatedβ2-microglobulin levels were strongly related to 17p deletion in our target population (p-value-0.005).
Conclusion: 17p deletion was a fairly common finding among patients of chronic lymphocytic leukaemia presenting to our department. Patients with elevated β2-microglobulin levels were more at risk of having this genetic mutation than those with normal β2-microglobulin levels.
Downloads
References
Hao T, Li-Talley M, Buck A, Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep 2019; 9(1): 12070. https://doi.org/10.1038/s41598-019-48445-1
Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol 2018 ; 5(1): e14-e24. https://doi.org/10.1016/S2352-3026(17)30232-6
Milne K, Sturrock B, Chevassut T. Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. Curr Oncol Rep 2020; 22(4): 36. https://doi.org/10.1007/s11912-020-0893-0
Roth SC. What is genomic medicine?. J Med Libr Assoc 2019; 107(3): 442-448. https://doi.org/10.5195/jmla.2019.604
Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program 2017; 2017(1): 329-337
.https://doi.org/10.1182/asheducation-2017.1.329
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910-1916
Yuan YY, Zhu HY, Wu JZ, Xia Y, Liang JH, Wu W, et al. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2019 ; 58(1): 43-51.
https://doi.org/10.1002/gcc.22692
Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, et al. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunotherapy Cancer 2019; 7(1): 22.
https://doi.org/10.1186/s40425-019-0509-0
Haferlach C, Jeromin S, Nadarajah N, Zenger M, Kern W, Haferlach T. Cytogenetic and Molecular Genetic Clonal Evolution in CLL Is Associated with an Unmutated IGHV Status and Frequently Leads to a Combination of Loss of 17p and TP53 mutation. Blood 2016; 128 (22): 3213.
https://doi.org/10.1182/blood.V128.22.3213.3213
Mahmood R, Khan SA, Altaf C, Malik HS, Khadim MT. Clinico-hematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan. Blood Res 2018; 53(4): 276-280.
https://doi.org/10.5045/br.2018.53.4.276
Döhner H, Stilgenbauer S, Benner A, Eupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910–1916.
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 2019 ; 94(11): 1266-1287.
https://doi.org/10.1002/ajh.25595
Chauffaille MLLF, Zalcberg I, Barreto WG, Bendit I. Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. Hematol Transfus Cell Ther 2020; 42(3): 261-268.
https://doi.org/10.1016/j.htct.2020.05.005
Gentile M, Cutrona G, Neri A, Molica S, Ferrarini M, Morabito F. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009; 94(6): 887-888.
https://doi.org/10.3324/haematol.2009.005561
Khalid A, Zahid M, Rehman A, Ahmad ZU, Qazi S, Aziz Z. Clinico-epidemiological features of adult leukemias in Pakistan. J Pak Med Assoc 1997; 47(4): 119-122.
Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol 2018; 16(1): 129. https://doi.org/10.1186/s12957-018-1429-z
Yu L, Kim HT, Kasar S, Benien P, Du W, Hoang K, et al. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clin Cancer Res 2017; 23(3): 735-745.
https://doi.org/10.1158/1078-0432.CCR-16-0594
Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol 2018; 97(12): 2269-2278. https://doi.org/10.1007/s00277-018-3503-6
Greipp PT, Smoley SA, Viswanatha DS, Frederick LS. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol 2013; 163(3): 326-333. https://doi.org/10.1111/bjh.12534
Downloads
Published
Issue
Section
How to Cite
